A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

Elie El Rassy; Ziad Bakouny; Fouad Aoun; Fadi G Haddad; Ghassan Sleilaty; Tarek Assi; Joseph Kattan

doi:10.2217/imt-2017-0190

A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

Immunotherapy. 2018 Jun;10(8):657-663. doi: 10.2217/imt-2017-0190. Epub 2018 Mar 22.

Authors

Elie El Rassy¹, Ziad Bakouny¹, Fouad Aoun², Fadi G Haddad¹, Ghassan Sleilaty³, Tarek Assi¹, Joseph Kattan¹

Affiliations

¹ Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
² Department of Urology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
³ Department of Biostatistics, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

PMID: 29562804
DOI: 10.2217/imt-2017-0190

Abstract

Aim: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer.

Methods & materials: Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis.

Results: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.

Keywords: PD-1 inhibitor; PDL-1 inhibitor; atezolizumab; pembrolizumab; urothelial bladder cancer.

Publication types

Comparative Study
Meta-Analysis

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
Clinical Trials, Phase III as Topic
Humans
Network Meta-Analysis
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Salvage Therapy / methods*
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / secondary*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
Programmed Cell Death 1 Receptor
atezolizumab
pembrolizumab

Associated data

ClinicalTrials.gov/NCT00315237
ClinicalTrials.gov/NCT02256436
ClinicalTrials.gov/NCT02302807